CAR T-cell Products Shine, Reveal New Insights ...Middle East

Medscape - News
The 12-month response and progression-free survival rates in 152 real-world patients treated with tisagenlecleucel (Kymriah) for an approved indication were 48.4% and 26.4%, respectively. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( CAR T-cell Products Shine, Reveal New Insights )

Apple Storegoogle play

Also on site :